Currently, the predominant agents for treating AD are acetylcholinesterase inhibitors, which can enhance cholinergic neurotransmission in the synaptic cleft by inhibiting acetylcholine degeneration [8]. The gene discussed is ACHE; the disease is Alzheimer disease.